Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Incivek, Xolair Linked to Severe, Sometimes Deadly Reactions: Report May 9, 2014 Irvin Jackson Add Your Comments Nearly a thousand deaths were reported to federal health officials involving drug hypersensitivity reactions over the last year, according to a new report, which suggests that the rate of problems seen with the asthma drug Xolair and the hepatitis C treatment Incivek are high enough to raise questions about whether they should remain on the market. On May 7, the Institute for Safe Medication Practices (ISMP) released its QuarterWatch (PDF) report, which monitors adverse event reports submitted to the FDA each quarter and identifies any potential trends seen among the drug side effects. ISMP indicates that nearly 10% of all serious adverse events reported to the FDA over the past year involved drug hypersensitivity reactions, which was only outnumbered by the reports of nonspecific gastrointestinal ailments experienced after use of medications. Learn More About Xolair Lawsuit Side effects of Xolair may increase the risk of Heart Attacks and other serious problems. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Xolair Lawsuit Side effects of Xolair may increase the risk of Heart Attacks and other serious problems. Learn More SEE IF YOU QUALIFY FOR COMPENSATION In all, the FDA logged 147,318 cases of serious adverse drug events from March 2012 through March 2013, with 13,042, or 8.9%, of those involving hypersensitivity. About 4,045 hypersensitivity reports resulted in serious injury or death, with at least 966 deaths reported. ISMP indicates that potential hypersensitivity side effects of Incivek and Xolair raise particular concern, indicating that the hypersensitivity problems “were so frequently reported and severe that this risk should be carefully considered in deciding whether clinical use is appropriate.” Incivek, manufactured by Vertex, was approved in 2011 for the treatment of hepatitis C in combination with other antiviral drugs. ISMP found that 60% of new users reported developing rashes, with 16% of that group having rashes that covered 50% or more of the body. There were 14 patient deaths reported and 104 cases of severe cutaneous reactions, outnumbering all other drugs. In December 2012, the FDA issued a warning about the risk of serious skin reactions with Incivek, indicating that the medication has been associated with cases of Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN), which is a severe reaction that causes the skin to separate from the body and can be fatal. The FDA required the manufacturers to add a new Incivek black box warning about the possible drug interactions, which is the strongest label warning that can be placed on a prescription medication. The prior label already contained information about the risk of serious skin reactions. Treatment for SJS and TEN typically involves inpatient care at a hospital Burn Unit, and TEN can be fatal due to organ failure. It can also cause permanent blindness. The asthma drug Xolair, however, accounted for more cases of anaphylaxis than any other drug reported. The drug was linked to 59 cases of anaphylactic shock. Xolair already carries a “black box” warning due to the risk of anaphylaxis, which can cause trouble breathing, chest tightness, dizziness, fainting, itching, hives, and swelling of the mouth and throat. The warning indicates that some cases of anaphylaxis happened after the first dose, but patients could take Xolair for more than a year before anaphylaxis symptoms appear. Xolair, manufactured by Genentech, was approved by the FDA in 2003 for use among adults and children over the age of 12 who suffer from moderate to severe persistent asthma caused by airborne allergens. In 2009, the FDA warned that it found a disproportionate increase in heart problems linked to Xolair use. Side effects appeared to include ischemic heart disease, arrhythmias, cardiomyopathy, heart failure, pulmonary hypertension, cerebrovascular disorders and problems associated with blood clots, like pulmonary embolism. Tags: Asthma, Heart Disease, Hepatitis C, Hypersensitivity, Incivek, Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, Xolair Image Credit: | More Xolair Lawsuit Stories Xolair Side Effects May Cause Heart Problems, Cancer: FDA Warns September 29, 2014 Xolair Heart Problems Being Reviewed by Health Canada August 14, 2009 Xolair Heart Side Effects Lead to FDA Review July 17, 2009 1 Comments Samuel October 28, 2018 I had severe body rashes from head to scalp. Diagnosed as plaque psoriasis, it covered 90% of my body. There was a huge argument on what percentage was real. I still have plaque psoriasis, only mild now, but it was the most awful thing many doctors saw. I I have some photos. They may have taken some but i doubt it. My mind was severely affected too as they said people were prone to drug relapses .once, after treatment I had developedv bad scleroderma where my skin came off in huge square sheets and the worst itching possible . I was only able to stop scratching when I somehow fell asleep. The only treatment for this was enbrel, and it finaay healed after 3 months. Since my treatment with ribavirin,, incivek and interferon, I have never been the same. Unable to hold jobs due to psoriasis that continues to this day. In my opinion it also started my back pain, which an MRI revealed a severely damaged back,. I believe it caused my back to have chronic deprivation of nutrients required for a healthy back. Surgergery will be after November 6th. Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermCommentsThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Breast Cancer Survivors File BioZorb Tissue Marker Lawsuit After Implant Fails (Posted: yesterday) Six women have filed a joint, multiplaintiff BioZorb tissue marker lawsuit, all indicating that they suffered injuries and complications due to the recalled device’s defective design. MORE ABOUT: BIOZORB LAWSUITBioZorb Implant Lawsuit Alleges Tissue Marker Caused Swelling, Fluid Buildup and Chronic Pain (05/14/2025)Four Women File BioZorb Lawsuit Over Breast Tissue Marker Failures and Injuries (05/05/2025)Lawsuit Claims BioZorb Marker Caused Chronic Pain, Multiple Surgeries After Lumpectomy (04/14/2025) 6 Bard PowerPort Lawsuits Selected for Bellwether Trials in Federal MDL (Posted: 2 days ago) A federal judge has identified the six Bard PowerPort lawsuits that will serve as the first bellwether trials, to test allegations that the port catheters were defectively designed. MORE ABOUT: BARD POWERPORT LAWSUITCourt Indicates Bard PowerPort MDL Bellwether Lawsuits Should Include 3 Infection, 2 Thrombosis and 1 Fracture Case (05/06/2025)Lawyers Proposed 11 Bard Implantable Port Catheter Lawsuits as Bellwether Trial Candidates (04/30/2025)Bard PowerPICC Intravascular Catheter Leaks Linked to Reports of Serious Injuries: FDA (04/21/2025) MDL Judge Orders Paraquat Lawsuit Settlement Update By June 11, 2025 (Posted: 5 days ago) A federal judge has agreed to stay all case-specific discovery deadlines in Paraquat lawsuits, while the parties work to hammer out a settlement agreement to resolve thousands of claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSParaquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (04/16/2025)Appeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025)
Breast Cancer Survivors File BioZorb Tissue Marker Lawsuit After Implant Fails (Posted: yesterday) Six women have filed a joint, multiplaintiff BioZorb tissue marker lawsuit, all indicating that they suffered injuries and complications due to the recalled device’s defective design. MORE ABOUT: BIOZORB LAWSUITBioZorb Implant Lawsuit Alleges Tissue Marker Caused Swelling, Fluid Buildup and Chronic Pain (05/14/2025)Four Women File BioZorb Lawsuit Over Breast Tissue Marker Failures and Injuries (05/05/2025)Lawsuit Claims BioZorb Marker Caused Chronic Pain, Multiple Surgeries After Lumpectomy (04/14/2025)
6 Bard PowerPort Lawsuits Selected for Bellwether Trials in Federal MDL (Posted: 2 days ago) A federal judge has identified the six Bard PowerPort lawsuits that will serve as the first bellwether trials, to test allegations that the port catheters were defectively designed. MORE ABOUT: BARD POWERPORT LAWSUITCourt Indicates Bard PowerPort MDL Bellwether Lawsuits Should Include 3 Infection, 2 Thrombosis and 1 Fracture Case (05/06/2025)Lawyers Proposed 11 Bard Implantable Port Catheter Lawsuits as Bellwether Trial Candidates (04/30/2025)Bard PowerPICC Intravascular Catheter Leaks Linked to Reports of Serious Injuries: FDA (04/21/2025)
MDL Judge Orders Paraquat Lawsuit Settlement Update By June 11, 2025 (Posted: 5 days ago) A federal judge has agreed to stay all case-specific discovery deadlines in Paraquat lawsuits, while the parties work to hammer out a settlement agreement to resolve thousands of claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSParaquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (04/16/2025)Appeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025)